Cerity Partners LLC Has $12.58 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cerity Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,060 shares of the biopharmaceutical company's stock after acquiring an additional 512 shares during the period. Cerity Partners LLC's holdings in Regeneron Pharmaceuticals were worth $12,576,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on REGN. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a report on Monday. UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $964.88.

Remove Ads

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $9.44 during trading hours on Tuesday, hitting $561.62. 249,291 shares of the company's stock were exchanged, compared to its average volume of 706,872. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The stock has a market cap of $61.40 billion, a price-to-earnings ratio of 14.67, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock's 50-day moving average is $657.03 and its 200-day moving average is $749.93.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The company's revenue was up 10.3% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.